Low Molecular Weight Heparin Market
- 2026 年市場規模
- USD 5,073.90 Mn
- 2033 年預估規模
- USD 8,008.0 Mn
- 年複合成長率 CAGR
- 6.7%
以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。
授權報價
| Single User Price | $4,500 USD |
| Enterprise License | $10,000 USD |
完整報告名稱與涵蓋範圍
Low Molecular Weight Heparin Market, By Drug (Enoxaparin, Dalteparin, Nadroparin, Bemiparin, Tinzaparin, Others), By Packaging (Multi-vials, Prefilled Syringes), By Application (Deep Vein Thrombosis, Acute Coronary Syndrome (ACS), Pulmonary Embolism, Atrial Fibrillation), By End User (Hospitals (Private and Public), Clinics, Home), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
報告摘要
Low Molecular Weight Heparins (LMWH) are a form of pharmacological anticoagulant intervention which are derived from unfractionated heparin (UFH) by chemical or enzymatic depolymerisation to yield fragments that are around one third the size of heparin. Low molecular weight heparin is used for prophylaxis of deep vein thrombosis and pulmonary embolism, or thrombosis occurring in a broad spectrum of clinical indications, including general or orthopaedic surgery, neurosurgery, trauma, unstable angina, and myocardial infarction. LMWHs are however, associated with higher anticoagulant effect and provides higher bioavailability after subcutaneous administration, as compared to unfractionated heparin UFH, for thromboembolic indications. Low molecular weight heparin is the most suitable anticoagulant in case of complicated pregnancy, as it eliminates risk of crossing the placental membrane. Low-molecular-weight heparins (LMWHs), for example, dalteparin, enoxaparin, among others, are anticoagulants. Low molecular weight heparins administration is via subcutaneous injection; this has long-term implications on the choice of anticoagulant for prophylaxis, for example, in orthopedic patients recovering from joint replacement surgery or in the treatment of Deep Vein Thrombosis and Pulmonary Embolism (DVT/PE). Patients often dislike injections, especially self-administered ones, complaining of pain or bleeding with injection, and prefer an oral alternative.
Market Dynamics
Increasing number of people are being affected with Deep Vein Thrombosis (DVT) which will subsequently increase demand for Low Molecular Weight Heparins (LMWH). For instance, according to National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention (CDC), Furthermore, in July 2021, according to Centers for disease control and prevention, the precise number of people affected by deep vein thrombosis (DVT) or pulmonary embolism (PE) is unknown, although as many as 900,000 people could be affected each year in the United States. Estimates suggest that 60,000-100,000 American citizens in 2019 die of DVT/PE (also called venous thromboembolism, or VTE). A case study published in April 2017 in the Canadian Medical Association Journal noted that the risk of venous thromboembolism (VTE), which includes both DVT and pulmonary embolism (PE), increases 20-fold in male-to-female people using hormone treatment, especially estrogen. A meta-analysis published in 2019 in the Journal of Blood Medicine reviewed 13 studies that looked at the effects of hormone therapy, including which types of estrogen are used, on transgender men and women. It found that even though the risk of VTE increased with certain formulations of hormone therapy, the absolute clinical risk is low.
Key features of the study
• This report provides an in-depth analysis of the global low molecular weight heparin market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global low molecular weight heparin market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Pfizer, Inc., LEO Pharma A/S, Sanofi S.A., Teva Pharmaceutical Industries Ltd., Amphastar Pharmaceuticals Inc., Abbott Laboratories, Aspen Pharmacare Holdings, Laboratorios Farmaceuticos ROVI SA, Changzhou Qianhong Biopharma, and Intrapharm Laboratories.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global low molecular weight heparin market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global low molecular weight heparin market
Market Segmentation
• By Drug
o Enoxaparin
o Dalteparin
o Nadroparin
o Bemiparin
o Tinzaparin
o Others
• By Packaging
o Multi-vials
o Prefilled Syringes
• By Application
o Deep Vein Thrombosis
o Acute Coronary Syndrome (ACS)
o Pulmonary Embolism
o Atrial Fibrillation
• By End User
o Hospitals
Private
Public
o Clinics
o Home
• By Region
o North America
U.S.
Canada
o Latin America
Brazil
Argentina
Mexico
Rest of Latin America
o Europe
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
o Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
o Middle East & Africa
GCC Countries
Israel
Rest of Middle East & Africa
• Key Players
o Pfizer, Inc.
o LEO Pharma A/S
o Sanofi S.A.
o Teva Pharmaceutical Industries Ltd.
o Amphastar Pharmaceuticals Inc.
o Abbott Laboratories
o Aspen Pharmacare Holdings
o Laboratorios Farmaceuticos ROVI SA
o Changzhou Qianhong Biopharma
o Intrapharm Laboratories
目錄 Table of Contents
Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
Market Definition and Scope
o Executive Summary
Market Snapshot, By Drug
Market Snapshot, By Packaging
Market Snapshot, By Application
Market Snapshot, By End User
Market Snapshot, By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
Drivers
Restraints
Market Opportunities
o Impact Analysis
o Epidemiology
o Key Developments
o Strategic Acquisitions
o Advantages of LMWH over UFH
o Cost-effectiveness of LMWH vs. UFH
o Shortage of Enoxaparin & Estimated Resupply Dates
o Drug Delivery Systems
o Regulatory Scenario
o Reimbursement Scenario
o Buy-and-bill and White Bagging Channel
o PEST Analysis
4. Global Low Molecular Weight Heparin Market, By Drug, 2026 – 2033, (USD Mn)
o Overview
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2026 – 2033
Segment Trends
o Enoxaparin
Overview
Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Mn)
o Dalteparin
Overview
Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Mn)
o Nadroparin
Overview
Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Mn)
o Bemiparin
Overview
Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Mn)
o Tinzaparin
Overview
Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Mn)
o Others
Overview
Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Mn)
5. Global Low Molecular Weight Heparin Market, By Packaging, 2026 – 2033, (USD Mn)
o Overview
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2026 – 2033
Segment Trends
o Multi-vials
Overview
Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Mn)
o Prefilled Syringes
Overview
Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Mn)
6. Global Low Molecular Weight Heparin Market, By Application, 2026 – 2033, (USD Mn)
o Overview
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2026 – 2033
Segment Trends
o Deep Vein Thrombosis
Overview
Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Mn)
o Acute Coronary Syndrome (ACS)
Overview
Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Mn)
o Pulmonary Embolism
Overview
Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Mn)
o Atrial Fibrillation
Overview
Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Mn)
7. Global Low Molecular Weight Heparin Market, By End User, 2026 – 2033, (USD Mn)
o Overview
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2026 – 2033
Segment Trends
o Hospitals
Overview
Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Mn)
o Private
Overview
Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Mn)
o Public
Overview
Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Mn)
o Clinics
Overview
Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Mn)
o Home
Overview
Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Mn)
8. Global Low Molecular Weight Heparin Market, By Region, 2026 – 2033, (USD Mn)
o Introduction
Market Share Analysis, By Region, 2026 and 2033 (%)
Y-o-Y Growth Analysis, For Regions, 2026–2033
Regional Trends
o North America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug, 2026 - 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Packaging, 2026 - 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 – 2033, (USD Mn)
o U.S.
o Canada
o Latin America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug, 2026 - 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Packaging, 2026 - 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 – 2033, (USD Mn)
o Brazil
o Mexico
o Argentina
o Rest of Latin America
o Europe
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug, 2026 - 2033, Market Size and Forecast, and Y-o-Y Growth, By Drug, 2026 - 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Packaging, 2026 - 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 – 2033, (USD Mn)
o U.K.
o Germany
o Italy
o France
o Spain
o Russia
o Rest of Europe
o Asia Pacific
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug, 2026 - 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Packaging, 2026 - 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 – 2033, (USD Mn)
o China
o India
o Japan
o ASEAN
o Australia
o South Korea
o Rest of Asia Pacific
o Middle East
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug, 2026 - 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Packaging, 2026 - 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 – 2033, (USD Mn)
o GCC
o Israel
o Rest of Middle East
o Africa
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug, 2026 - 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Packaging, 2026 - 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 – 2033, (USD Mn)
o North Africa
o Central Africa
o South Africa
9. Competitive Landscape
o Heat Map Analysis
o Company Profiles
Pfizer, Inc.
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Key Strategies
LEO Pharma A/S
o Company Overview
o Drug Portfolio
o Financial Performance
o Recent Developments/Updates
o Key Strategies
Sanofi S.A.
o Company Overview
o Drug Portfolio
o Financial Performance
o Recent Developments/Updates
o Key Strategies
Teva Pharmaceutical Industries Ltd.
o Company Overview
o Drug Portfolio
o Financial Performance
o Recent Developments/Updates
o Key Strategies
Amphastar Pharmaceuticals Inc.
o Company Overview
o Drug Portfolio
o Financial Performance
o Recent Developments/Updates
o Key Strategies
Aspen Pharmacare Holdings
o Company Overview
o Drug Portfolio
o Financial Performance
o Recent Developments/Updates
o Key Strategies
Laboratorios Farmaceuticos ROVI SA
o Company Overview
o Drug Portfolio
o Financial Performance
o Recent Developments/Updates
o Key Strategies
Changzhou Qianhong Biopharma
o Company Overview
o Drug Portfolio
o Financial Performance
o Recent Developments/Updates
o Key Strategies
Intrapharm Laboratories
o Company Overview
o Drug Portfolio
o Financial Performance
o Recent Developments/Updates
o Key Strategies
10. Section
o References
o Research Methodology
o About Us and Sales Contact
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們